ReviewEuropean respiratory review : an official journal of the European Respiratory Society2025
CD146: a promising target in respiratory diseases.
Review in European respiratory review : an official journal of the European Respiratory Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Surface marker-defined functional subpopulations of mesenchymal stromal cells: mechanisms, applications, and clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- Biological properties of soluble CD146 and its role and mechanisms in disease progression.Frontiers in immunology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory diseases are major causes of chronic disorders and death worldwide, involving inflammatory, tumoral or infectious processes. It has been proven that vascular mechanisms are key contributors to the pathogenesis of these diseases. For that purpose, it is essential to describe and validate new biomarkers and/or therapeutic targets responsible for lung vascularisation and/or angiogenesis. CD146 is an endothelial cell adhesion molecule also expressed on mesenchymal stem cells, epithelial cells and T-helper 17 lymphocytes. A soluble form of CD146 exists, sCD146, which can be detected in blood and biological samples, including the bronchoalveolar lavage fluid. CD146/sCD146 are involved in angiogenesis and inflammation and are associated with many inflammatory diseases. Recent studies have reported both protective and detrimental roles of CD146/sCD146 in lung diseases. In the present review, we will describe the potential role of CD146 and sCD146 in the pathogenesis of respiratory diseases in order to use them as key mechanistic biomarkers or new therapeutical targets to treat or even cure these pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.